Skip to main content

Table 2 Clinical and ultrasound parameters at baseline and after 12 months in total population, group of responders and non-responders

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

 

Month of visit 0 (V0)*

Month of visit 12 (V12)*

Difference between V12 and V0*

p value (Wilcoxon signed rank test)

Total population (n = 35 for clinical, n = 34 for US7 parameters)

 28-SJC

5 (3;9.5)

(1;20)

1 (0;2)

(0;10)

−4 (−7;− 1)

(−19;3)

< 0.001 (sig.)

 28-TJC

7 (3.5;15)

(1;25)

1 (0;3)

(0;26)

−4 (− 10;− 1)

(−24;6)

< 0.001 (sig.)

 DAS28(ESR)

5.61 (4.8;6.23)

(3.55;7.57)

3.31 (2.45;3.98)

(1.13;6.19)

−2.22 (−3.11;− 1.39)

(−5.45;0.56)

< 0.001 (sig.)

 GS-synovitis

7 (5.5;9.5)

(2;15)

6 (4.25;7)

(2;10)

− 1 (−3;0)

(−9;7)

0.0112 (sig.)

 GS-tenosynovitis

3 (2;4)

(0;5)

2.5 (2;3)

(0;4)

−0.5 (−1.75;0)

(−4;2)

0.0239 (sig.)

 PD-synovitis

4 (3;7)

(2;15)

3 (2;3.75)

(0;11)

−1 (−3;0)

(−9;1)

0.00004 (sig.)

 PD-tenosynovitis

3 (2;4)

(0;7)

2 (1.25;3)

(0;5)

0 (−2;0.75)

(−4;1)

0.0163 (sig.)

Group of responders (n = 16)

 28-SJC

3.5 (1.75;8.25)

(1;15)

0 (0;1)

(0;3)

−3.5 (−8.25;− 1) (−14;1)

0.002 (sig.)

 28-TJC

4.5 (3;10.5)

(1;24)

0 (0;0.25)

(0;2)

−3.5 (−10.5;− 3) (−24;− 1)

< 0.001 (sig.)

 DAS28(ESR)

4.88 (4.33;6.18)

(3.55;7.33)

2.38 (1.89;2.68)

(1.13;3.18)

−2.82 (−3.82;− 1.82)

(−5.45;− 1.14)

< 0.001 (sig.)

 GS-synovitis

8 (6;9.25)

(2;12)

6 (4;7)

(3;9)

−2 (−4.25;0)

(−9;7)

0.038 (sig.)

 GS-tenosynovitis

4 (2.75;5)

(1;5)

2.5 (2;3)

(1;4)

−1 (−2;0)

(−4;2)

0.0274 (sig.)

 PD-synovitis

4 (3.75;6.5)

(2;11)

3 (2;3)

(1;4)

−2 (−5;− 0.75)

(−8;1)

0.0028 (sig.)

 PD-tenosynovitis

3 (2;5)

(1;7)

2 (2;3)

(1;3)

−1 (−2.25;0)

(−4;1)

0.01 (sig.)

Group of non-responders (n = 19 for clinical, n = 18 for US7 parameters)

 28-SJC

6 (3.5;9.5)

(1;20)

1 (0;4)

(0;10)

−5 (−6.5;− 2)

(−19;3)

0.001 (sig.)

 28-TJC

11 (5.5;18.5)

(1;25)

3 (1.5;11)

(0;26)

−4 (−8;0.5)

(−22;6)

0.01 (sig.)

 DAS28(ESR)

5.82 (5.34;6.23)

(3.61;7.57)

3.95 (3.51;5.21)

(3.28;6.19)

−1.62 (−2.61;− 0.51)

(−3.73;0.56)

< 0.001 (sig.)

 GS-synovitis

7 (4.5;9.5)

(2;15)

6 (5;8.5)

(2;10)

−1 (−2;0.75)

(−5;6)

0.1641

 GS-tenosynovitis

2 (2;4)

(0;5)

2.5 (1;3)

(0;4)

0 (−1;1)

(−3;2)

0.506

 PD-synovitis

4 (2.5;7)

(2;15)

3 (1;5)

(0;11)

−1 (−2;0)

(−9;1)

0.0058 (sig.)

 PD-tenosynovitis

2 (1;3)

(0;7)

2.5 (1;3)

(0;5)

0 (−0.75;1)

(−4;1)

0.7732

  1. Clinical and ultrasound (US) parameters at baseline and after 12 months in total population, group of responders and non-responders: *Median (1. quartile; 3. quartile); (min; max), significance level = 0.05; 28-SJC swollen joint count of 28 joints, 28-TJC tender joint count of 28 joints, DAS28(ESR) Disease Activity Score of 28 joints and erythrocyte sedimentation rate (ESR), GS greyscale mode in ultrasound, PD Power Doppler mode in ultrasound
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us